Price
Financials
Standalone, Rs crore| Mar 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 15.92 | 53.52 | 2.05 |
| Expenses | 14.64 | 51.87 | 1.59 |
| Operating Profit | 1.28 | 1.65 | 0.46 |
| OPM % | 8.04% | 3.08% | 22.44% |
| Other Income | 0.00 | 0.00 | 0.00 |
| Interest | 0.60 | 0.23 | 0.23 |
| Depreciation | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.68 | 1.42 | 0.23 |
| Tax % | 26.47% | 26.06% | 21.74% |
| Net Profit | 0.50 | 1.04 | 0.18 |
| EPS in Rs | 0.21 | 0.40 | 0.07 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | 129 |
| Expenses | 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | 124 |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 |
| OPM % | 2.4% | 2.4% | 1.5% | 1.3% | 3.0% | 2.4% | 2.1% | 3.0% | 3.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 4 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% | 26% |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 |
| EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 | 1.00 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 33% | 9% | 4% | ||
| Compounded Profit Growth | % | 165% | 42% | 171% | ||
| Stock Price CAGR | % | % | -27% | -76% | ||
| Return on Equity | % | 5% | 4% | 5% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 | 26 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 | 36 |
| Borrowings | 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | 13 |
| Other Liabilities | 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | 130 |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -3 | -2 | 3 | -21 | -5 | -9 | -18 | ||
| Cash from Investing Activity | 0 | 0 | -0 | -0 | -0 | -0 | -0 | ||
| Cash from Financing Activity | 3 | 2 | -3 | 26 | 14 | -4 | 19 | ||
| Net Cash Flow | 0 | 0 | -0 | 5 | 8 | -13 | 0 | ||
| Free Cash Flow | -3 | -2 | 3 | -21 | -5 | -9 | -18 | ||
| CFO/OP | -693% | -618% | 148% | -893% | -157% | -246% | -347% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 | 136 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 | 144 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 | 375 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 | -95 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 | 56 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% | 8% |
| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Nov 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 66.56% | 66.56% | 57.19% | 9.98% | 9.98% | 9.98% | 9.98% | 9.13% | 9.13% | 9.13% |
| Public | 33.45% | 33.43% | 42.81% | 90.02% | 90.02% | 90.01% | 90.02% | 90.87% | 90.88% | 90.86% |
| No. of Shareholders | 1,110 | 992 | 1,078 | 1,807 | 2,652 | 1,997 | 1,742 | 1,741 | 1,717 | 1,788 |
Fundamentals
Market Cap₹ 12.0 Cr.
Current Price₹ 4.57
Stock P/E4.57
Book Value₹ 23.7
ROCE7.64 %
ROE5.22 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)171%
Standalone figures.
Valuation
Market capRs 10 Cr
Enterprise valueRs 27 Cr
P/E (TTM)10.29x
Price to book0.26x
Price to sales0.08x
EV / EBITDA7.14x
EV / EBIT7.16x
EV / sales0.21x
Earnings yield9.72%
P/E, 3-year average23.27x
P/B, 3-year average0.67x
P/E, 5-year average23.27x
P/B, 5-year average0.67x
Profitability
Operating margin (excl. other income)3.00%
Operating margin (incl. other income)3.01%
EBITDA margin3.01%
Pre-tax margin1.14%
Net profit margin0.78%
ROE2.55%
ROCE6.64%
ROA0.73%
ROE, 3-year average4.35%
ROCE, 3-year average7.57%
ROA, 3-year average1.12%
ROE, 5-year average23.49%
ROCE, 5-year average8.73%
ROA, 5-year average1.46%
ROIC (approx.)4.62%
Tax rate31.69%
Other income / net worth0.03%
Growth
Sales growth (latest year)-24.11%
Profit growth (latest year)-11.01%
Sales CAGR, 3 years19.70%
Sales CAGR, 5 years32.54%
Profit CAGR, 3 years-6.06%
Profit CAGR, 5 years74.47%
Per share
EPS (TTM)Rs 0.40
EPS (latest year)Rs 0.40
EPS, 3-year averageRs 0.54
EPS, 5-year averageRs 68.32
Book value per shareRs 16.01
Sales per shareRs 51.85
Cash flow per shareRs -3.82
Free cash flow per shareRs -7.49
Efficiency
Asset turnover0.94x
Fixed asset turnover2493.60x
Inventory turnover4.15x
Inventory days88 days
Debtor days135 days
Debtors turnover2.69x
Creditor days375 days
Cash conversion cycle-95 days
Working capital days56 days
Leverage
Total debtRs 17 Cr
Cash and bankRs 0 Cr
Net debtRs 17 Cr
Debt to equity0.45x
Net debt / EBITDA4.48x
Interest coverage1.61x
Owners' fund to total sources29.08%
Debt to assets13.01%
Cash flow
Cash from Operating Activity (latest year)Rs -9 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs -4 Cr
Net Cash Flow (latest year)Rs -13 Cr
Free cash flow (latest year)Rs -18 Cr
FCFE (approx.: FCF + change in debt)Rs -20 Cr
Cash from ops / profit, 5 years-7.14x
Statement figures
Net sales (TTM)Rs 125 Cr
Net sales (latest year)Rs 125 Cr
Operating profit excl. other income (latest year)Rs 4 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 4 Cr
PBDT (TTM)Rs 1 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 1 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 114 Cr
Total expenditure (latest year)Rs 121 Cr
Total income (latest year)Rs 125 Cr
Share capitalRs 24 Cr
ReservesRs 14 Cr
Shareholders' fundsRs 38 Cr
Total assetsRs 132 Cr
Net blockRs 0 Cr
ReceivablesRs 46 Cr
InventoryRs 27 Cr
Other liabilitiesRs 77 Cr
Shares outstanding (crore)2.40
Ownership
Promoter holding9.13% (-0.85 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 10.3 is the lowest in its own 3.4-year history
(median 21.5, low 10.3, high 59.3).
P/B 0.26 is the lowest in 4.2 years (median 1.48).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 543594 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -12.3% | -2.8% | -9.5 pts |
| 1 month | -25.9% | -6.8% | -19.1 pts |
| 3 months | -40.9% | -7.6% | -33.3 pts |
| 3 years | -64.9% | +14.2% | -79.1 pts |
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was -1198% of net profit over the last 3 years |
| explain | Receivables outrunning sales Receivables grew 50% vs sales -24% in 2026 |
| explain | Share dilution Share count up 0% in a year, 23900% in three |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd (543594) has a market capitalisation of Rs 12.0 Cr. at the 2026-10-01 close.
What is the P/E ratio of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd trades at a P/E of 4.57 on trailing twelve-month profit, at the 2026-10-01 close.